Cytori Therapeutics has announced that its Kerastem Technologies brand has completed a stage II trial investigating male and female pattern hair loss.
Cytori Cell Therapy underwent a randomised, blinded and controlled study that included 70 patients in the US with early stage male and female pattern baldness.
This form of hair loss, known as Androgenic Alopecia is the most common form of alopecia in the US.
The therapy involves collecting tissue from elsewhere in the body and processing it to obtain stem cells from fat, purified fat and enriched fat. This is then and injected into affected areas on the scalp.